UnitedHealthcare Pharmacy
Clinical Pharmacy Programs
Program Number 2024 P 2107-14
Program Prior Authorization – Medical Necessity
Medication Cequa™ (cyclosporine 0.09% ophthalmic solution)*, Restasis®
MultiDose™ (cyclosporine 0.05% ophthalmic emulsion)*, Tyrvaya™
(varenicline nasal spray), Vevye™ (cyclosporine 0.1%)*
P&T Approval Date 9/2016, 9/2017, 9/2018, 3/2019, 4/2020, 4/2021, 12/2021, 7/2022,
7/2023, 9/2023, 3/2024, 7/2024
Effective Date 8/18/2024
1. Background:
Cequa (cyclosporine 0.09% ophthalmic solution)* and Restasis MultiDose (cyclosporine 0.05%
ophthalmic emulsion)* are indicated to increase tear production in patients whose tear
production is presumed to be suppressed due to ocular inflammation associated with
keratoconjunctivitis sicca.
Tyrvaya (varenicline nasal spray), Vevye (cyclosporine 0.1%)* and Xiidra (lifitegrast 5%
ophthalmic solution) are indicated for the treatment of the signs and symptoms of dry eye
disease.
2. Coverage Criteria a:
A. Cequa*, Restasis MultiDose* or Vevye*
1. Initial Authorization
a. Cequa*, Restasis MultiDose* or Vevye* will be approved based on all of the
following:
(1) Tear deficiency associated with ocular inflammation due to one of the
following:
(a) Moderate to severe keratoconjunctivitis sicca
-OR-
(b) Moderate to severe dry eye disease
-AND-
(2) Not prescribed to manage dry eyes peri-operative elective eye surgery (e.g.:
LASIK)
-AND-
© 2024 UnitedHealthcare Services, Inc.
1
(3) History of failure to at least one OTC artificial tear product (e.g., Systane®
Ultra, Akwa® Tears, Refresh Optive®, Soothe® XP)
-AND-
(4) History of failure, contraindication or intolerance to both of the following:
(a) Restasis single dose vials
(b) Xiidra
-AND-
(5) Medication will not be used in combination with another prescription product
for dry eye disease or keratoconjunctivitis sicca (e.g., Miebo, Restasis single
dose-vials, Tyrvaya, Xiidra)
-AND-
(6) Prescribed by or in consultation with one of the following:
(a) Ophthalmologist
(b) Optometrist
(c) Rheumatologist
Authorization will be issued for 12 months.
2. Reauthorization
a. Cequa*, Restasis MultiDose*, or Vevye* will be approved based on the following
criterion:
(1) Patient has demonstrated clinically significant improvement with therapy
-AND-
(2) Medication will not be used in combination with another prescription product for
dry eye disease or keratoconjunctivitis sicca (e.g., Miebo, Restasis single dose-
vials, Tyrvaya, Xiidra)
Authorization will be issued for 12 months.
B. Tyrvava
1. Initial Authorization
a. Tyrvaya will be approved based on all of the following:
(1) Tear deficiency associated with ocular inflammation due to one of the
following:
(a) Moderate to severe keratoconjunctivitis sicca
© 2024 UnitedHealthcare Services, Inc.
2
-OR-
(b) Moderate to severe dry eye disease
-AND-
(2) Not prescribed to manage dry eyes peri-operative elective eye surgery (e.g.:
LASIK)
-AND-
(3) History of failure to at least one OTC artificial tear product (e.g., Systane®
Ultra, Akwa® Tears, Refresh Optive®, Soothe® XP)
-AND-
(4) History of failure, contraindication or intolerance to both of the following:
(a) Restasis single dose vials
(b) Xiidra
-AND-
(5) Medication will not be used in combination with another prescription product
for dry eye disease or keratoconjunctivitis sicca (e.g., Cequa, Miebo, Restasis,
Vevye, Xiidra)
-AND-
(6) Prescribed by or in consultation with one of the following:
(a) Ophthalmologist
(b) Optometrist
(c) Rheumatologist
Authorization will be issued for 12 months.
2. Reauthorization
a. Tyrvaya will be approved based on the following criterion:
(1) Patient has demonstrated clinically significant improvement with therapy
-AND-
(2) Medication will not be used in combination with another prescription product
for dry eye disease or keratoconjunctivitis sicca (e.g., Cequa, Miebo, Restasis,
Vevye Xiidra)
Authorization will be issued for 12 months.
© 2024 UnitedHealthcare Services, Inc.
3
a. State mandates may apply. Any federal regulatory requirements and the member specific
benefit plan coverage may also impact coverage criteria. Other policies and utilization
management programs may apply.
*Cequa, Restasis MultiDose and Vevye* are typically excluded from coverage.
3. Additional Clinical Rules:
• Notwithstanding Coverage Criteria, UnitedHealthcare may approve initial and re-authorization
based solely on previous claim/medication history, diagnosis codes (ICD-10) and/or claim logic.
Use of automated approval and re-approval processes varies by program and/or therapeutic class.
• Supply limits may be in place
• Prior Authorization – Notification may be in place
4. References:
1. Cequa [package insert]. Cranbury, NJ: Sun Pharmaceutical Industries, Inc; December 2022.
2. Restasis [package insert]. Irvine, CA: Allergan, Inc.; July 2017.
3. Restasis MultiDose [package insert]. Irvine, CA: Allergan, Inc.; October 2016.
4. Tyrvaya [package insert]. Princeton NJ: Oyster Point Pharma, Inc; February 2024
5. Vevye [package insert]. Nashville, TN: Harrow Eye, LLC; November 2023.
6. Xiidra [package insert]. Bridgewater, NJ: Bausch & Lomb Americas Inc;December 2023.
7. American Academy of Ophthalmology. Dry Eye Syndrome Preferred Practice Pattern 2023.
Program Prior Authorization – Medical Necessity – Dry Eye Disease
Change Control
9/2016 New program.
11/2016 Administrative change. Added California coverage information.
9/2017 Annual review. Administrative updates. Added Restasis MultiDose.
Updated references.
9/2018 Annual review. Administrative updates and updated references.
12/2018 Administrative change to add statement regarding use of automated
processes.
3/2019 Added Cequa and updated references.
4/2020 Annual review. Added a step through Restasis single use vials for
Cequa and Restasis MultiDose. Updated references.
4/2021 Annual review. Updated references.
12/2021 Added Tyrvava.
7/2022 Removed Restasis single dose vials and Xiidra from the criteria.
7/2023 Annual review. Added step through Xiidra for Cequa & Restasis
Multidose. Updated references.
9/2023 Added Miebo and Vevye.
3/2024 Updated the initial authorization to 12 months. Updated references.
7/2024 Removed Miebo from Medical Necessity criteria. Added language on
concomitant therapy. Removed referenced to compound Notification.
© 2024 UnitedHealthcare Services, Inc.
4